Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Lilani P. Perera MD
Assistant Professor
Department of Medicine
Division of Gastroenterology

OFFICE ADDRESS:
Froedtert East Clinics
9200 W Wisconsin Ave
Milwaukee, WI 53226

CITIZENSHIP:  Sri Lanka, USA

EDUCATION:
5/1993 - 12/1998 MBBS/MD, Colombo Medical College, University of Colombo, colombo, Sri Lanka
1/1999 - 5/2000 ECFMG Certification

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
6/2001 - 6/2002 Internship, Internal Medicine, Saint Barnabas Medical Center, Livingston, NY
7/2002 - 7/2004 Residency, Internal Medicine, Saint Barnabas Medical Center, Livingston, NY
7/2004 - 6/2005 Research Fellowship, Immunobiology Center, The Mount Sinai Medical Center, New York, NY
7/2005 - 6/2008 Fellowship, Gastroenterology and Hepatology, The Medical College of Wisconsin, Milwaukee, WI

FACULTY APPOINTMENTS:
7/2008 - Present Assistant Professor of Medicine, The Medical College of Wisconsin, Division of Gastroenterology and Hepatology, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
6/2000 - 6/2001 Assistant Researcher, Immunobiology Center, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029

HOSPITAL STAFF PRIVILEGES:
7/2008 - Present Zablocki VA Medical Center, 5000 W National Avenue, Milwaukee, Wisconsin 53295
7/2008 - Present Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Avenue, Milwaukee, Wisconsin 53226

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Internal Medicine
8/2004
12/2014
ABIM - Gastroenterology
11/2008
12/2018
 
Certificates
Issued By Issue DateExpiration
ACLS
4/2009
4/2011
 
Licensure
Number Issue DateExpiration
Wisconsin Licen
12/2005
10/2011
 
AWARDS AND HONORS:
5/1993 - 12/1998 Full academic scholarship, Ministry of Higher Education, Colombo, Sri Lanka
12/1998 MBBS with honors
6/2002 - 6/2003 Albert N. Seigel, M.D., Memorial Award for Excellence in Gastroenterology, Saint Barnabas Medical Center, Livingston, NJ
6/2003 - 6/2004 Resident Research Scholarship Award for Outstanding Research and Scholarship, Saint Barnabas Medical Center, Livingston NJ
2008 Salix Fellow Travel Grant
2010 WeCare Travel Grant

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Gastroenterological Association
Crohn's and Colitis of America (CCFA)
American College of Physicians
American Medical Association
American Society of Gastrointestinal Endoscopy

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
High Prevalence of Anorectal Dysfunction in Patients with Quiescent IBD
Source:
Digestive Disease Center
Role:
Principal Investigator
Dates:
12/2009 - 9/2011
Direct Funds:
$20,000
 
Title:
High Prevalence of Anorectal Dysfunction in Patients with Quiescent IBD
Source:
Froedtert Hospital Foundation Grant
Role:
Principal Investigator
Dates:
12/2009 - 12/2010
Direct Funds:
$10,000
 
Title:
C13011- A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients with Moderate to Severe Crohn’s Disease
Source:
Millennium
Role:
Principal Investigator
 
Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2mg/25 ML BID for 2 Weeks, Followed by 2mg/25ML QD for 4 Weeks) Versus Placebo in Subjects with Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Source:
Salix
Role:
Principal Investigator
 
Title:
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease
Source:
UCSF Center for Colitis and Crohn's Disease
Role:
Principal Investigator
 
Title:
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Crohn's Disease
Source:
Millennium
Role:
Principal Investigator
 
Title:
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease
Source:
Millennium
Role:
Principal Investigator
 
Title:
SECURE- A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn's Disease
Source:
UCB Pharmaceuticals
Role:
Principal Investigator
 
Title:
Protocol # C0524T18 -A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis
Source:
Abbott
Role:
Principal Investigator
 
Title:
A Phase IIB, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease-Protocol #M10-222
Source:
Abbott
Role:
Principal Investigator
 
Title:
Protocol C13006 - A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis
Source:
Millennium
Role:
Principal Investigator
 
Prior
Peer Review
Title:
Protocol # C0524T18 -A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis
Source:
Centocor
Role:
Principal Investigator
 
Title:
Protocol # C0524T17 - A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis
Source:
Centocor
Role:
Principal Investigator
 
PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
1. 36. Naik AS, Zadvornova Y, Stein DJ, Shastri N, Venu M, Best K, Perera LP, Saeian K, Venu N. , Factors Associated With 30 Day Re-Admission in Inflammatory Bowel Disease. , Digestive Disease Week 2013, Orlando, FL
 
International
1. Kumar N, Ananthakrishnan AN, Zadvornova Y, Issa M, Naik AS, Perera LP. Durablility of Infliximab in Ulcerative Colitis: a tertiary center experience. Presented as a poster at Digestive Disease Week, 2010
2. Perera LP, Ananthakrishnan AN, Zadvornova Y, Issa M, Naik AS, Skaros S, Johnson K, Tyler K, Ward A, Massey B. High prevalence of obstructive defecation in Inflammatory Bowel Disease patients in remission. Presented as a poster at Digestive Disease Week, 2010
3. Ananthakrishnan AN, Naik AS, Zadvornova Y, Issa M, Skaros S, Johnson K, Tyler K, Ward A, Perera, LP. Pregnancy and Health Related Quality of Life (HRQoL) in IBD: A tertiary care observational Study. Presented as a poster at Digestive Disease Week, 2010
4. Venu M, Naik AS, Ananthakrishnan AN, Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion D, Issa M. Early Infliximab infusion in hospitalized severe UC patients: two year outcome. Presented as a poster at Digestive Disease Week, 2010
5. Zadvornova Y, Ananthakrishnan AN, Stein D, Skaros S, Johnson K, Naik AS, Perera LP, Issa M. Infliximab monotherapy vs. combined Infliximab-immunomodulator therapy in Ulcerative Colitis. Presented as a poster at Digestive Disease Week, 2010
6. Naik AS, Zadvornova Y, Issa M, Skaros S, Ward A, Johnson K, Tyler K, Stein D, Perera LP, Ananthakrishnan, AN. Tubular Adenoma and Low Grade Dysplasia in Inflammatory Bowel Disease: Who is at risk? Presented as a poster at Digestive Disease Week, 2010
7. Issa M, Zadvornova Y, Naik AS, Stein D, Venu N, Perera LP. High rates of escalation and termination of adalimumab therapy and patients exposed to infliximab. Presented as a poster at Digestive Disease Week, 2011
8. Liu R, Oimoen K, Zadvornova Y, Pruszynski J, Naik AS, Stein D, Venu N, Perera LP. Advanced age at diagnosis does not negatively impact health related quality of life in IBD: Performance of SIBDQ in a longterm cohort study. Presented as a poster at Digestive Disease Week, 2011
9. Issa M, Zadvornova Y, Naik AS, Stein D, Venu N, Perera LP, Binion D, Naik AS. Long-term use of purine analogues in inflammatory bowel disease. Presented as a poster at Digestive Disease Week, 2011
10. Libot A, Issa M, Zadvornova Y, Stein D, Venu N, Perera LP, Naik AS. , Initial vancomycin monotherapy is associated with higher rates of subsequent clostridium difficile infection in inflammatory bowel disease population. Presented as a poster at Digestive Disease Week, 2011
11. Chiplunker A, Zadvornova Y, Issa M, Stein D, Perera LP, Venu N, Naik AS. Factors associated with repeat hospitalizations in inflammatory bowel disease. Presented as a poster at Digestive Disease Week, 2011
12. Tarekegn S, Oimoen K, Zadvornova Y, Eastwood D, Issa M, Naik AS, Stein D, Venu N, Perera LP. Biologics are superior to immunomodulators in prevention of post-operative recurrence of Crohn's disease. Presented as a poster at Digestive Disease Week, 2011
 
EXTRAMURAL TEACHING (e.g. at Marquette, UWM, etc.):
Community/Lay Public
8/2010 - Present IBD Support Group Talk
 
Continuing Medical Education
3/2012 - 4/2013 IBD Update
 
COMMUNITY SERVICE ACTIVITIES:
6/2010 - 6/2013 Take Steps Walk for Crohn's & Colitis Foundation


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Perera L, Mayer L. Immunologic defects underlying the IBD. Gastroenterology & Hepatology. 2005 September;1(2):108-116.
2. Zauber NP, Sabbath SA, Morata S, Perera LP. Adequacy of colonoscopic biopsy specimens for molecular analysis: a comparative study with colectomy tissue. Diagnostic Molecular Pathology. 2006 September;15(3):162-8.
3. Perera LP, Jabri Bana, Saho Ling, Patel A, Mayer L: Class 1b expression defect in IBD epithelial cells: lack of coordinate regulation of CD1d and the epithelially expressed CD8 ligand, gp180. Inflammatory Bowel Diseases. 2007 March;13(3):298- 307.
4. Perera L, Kern M, Hofmann C, Tatro L, Chai K, Kuribayashi S, Lawal A, Shaker R. Manometric evidence for a phonation-induced UES contratile reflex. American Journal of Physiology, Gastrointestinal and Liver Physiology. 2008 April;294(4):G885-891.
5. Ananthakrishnan AN, Beaulieu DB, Ulitsky A, Zadvornova Y, Skaros S, Johnson K, Naik A, Perera L, Issa M, Binion DG, Saeian K. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Inflammatory Bowel Diseases. 2010 March;16(3):494-500.
6. Kuribayashi S, Massey BT , Hafeezullah M, Perera LP, Hussaini S, Tatro L, Darling R, Franco R, Shaker R. Upper esophageal sphincter and gastroesophageal junction pressure changes act to prevent gastroesophageal and esophagopharyngeal reflux during apneic episodes in patients with obstructive sleep apnea. Chest. 2010 April;137(4):769-776.
7. Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, Naik A, Perera L, Binion DG. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflammatory Bowel Diseases. 2011 January;17(1):77-83.
8. Ananthakrishnan AN, Beaulieu DB, Ulitsky A, Zadvornova Y, Skaros S, Johnson K, Naik A, Perera L, Issa M, Binion DG, Saeian K Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Inflamm Bowel Dis. 2010 Mar;16(3):494-500
9. Ananthakrishnan AN, Zadvornova Y, Naik AS, Issa M, Perera LP Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. J Dig Dis. 2012 Sep;13(9):472-7
10. Bautista MC, Otterson MF, Zadvornova Y, Naik AS, Stein DJ, Venu N, Perera LP Surgical outcomes in the elderly with inflammatory bowel disease are similar to those in the younger population. Dig Dis Sci. 2013 Oct;58(10):2955-62
11. Perera LP, Ananthakrishnan AN, Guilday C, Remshak K, Zadvornova Y, Naik AS, Stein DJ, Massey BT Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission. Dig Dis Sci. 2013 Dec;58(12):3600-5
12. Kuribayashi S, Massey BT, Hafeezullah M, Perera L, Hussaini SQ, Tatro L, Darling RJ, Franco R, Shaker R Terminating motor events for TLESR are influenced by the presence and distribution of refluxate. Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G71-5
13. Perera L, Kern M, Hofmann C, Tatro L, Chai K, Kuribayashi S, Lawal A, Shaker R Manometric evidence for a phonation-induced UES contractile reflex. Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G885-91
14. Perera L, Shao L, Patel A, Evans K, Meresse B, Blumberg R, Geraghty D, Groh V, Spies T, Jabri B, Mayer L Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis. 2007 Mar;13(3):298-307
 
Abstracts
1. Beuria P, Panja A, Kraus T, Perera L, Sperber K: Human intestinal epithelial cells constitutively express the B7h co stimulatory molecule. Gastroenterology. 2001 April;120(5, suppl 1): A-318(1643).
2. Yio X, Korsten C, Friedman C, Park M, Yio J, Roth-Walter F, Perera L, Kamalu O, Mayer L. Carcinoembryonic antigen expressing cells preferentially activate CD8+ T cells. Gastroenterology. 2006 April;130(4, suppl 2): A-693(W 1616).
3. Perera L, Chai K, Hoffman C, Rittman T, Kern M, Shaker R. Effect of phonation on the luminal pressures of the esophagus and its sphincters. Gastroenterology. 2006 April; 130(4, suppl 2): A-729(W1790).
4. Bajaj S, Blom D, Antonik SJ, Mepani R, Kern MK, Chai K, Perera LP, Hofmann C, Shaker R. Comparison of the effect of Dor procedure and Nissen fundoplicationon the dispensability of gastroesophageal junction; an intraoperative study. Gastroenterology. 2007 April;132(4, suppl 2): A-51(M1437).
5. Perera LP, Kern MK, Tatro L, Hofmann C, Kuribayashi S, Chai K, Shaker R. New insight into phonation induced increase in the upper esophageal sphincter pressure; contraction vs compression. Gastroenterology. 2007 April; 132(4, suppl 2): A595(T1973).
6. Perera LP, Tatro L, Hoffman C, Kern MK, Shaker R. Gender affects phonation related UES contraction. 2007 April;132(4, suppl 2): A-93(T1963).
7. Perera LP, Hofmann C, Hogan WJ, Massey BT. Use of amyl nitrite test to assess impaired LES relaxation during manometry. Gastroenterology. 2007 April; 132(4, suppl 2): A26(136).
8. Perera LP, Hoffmann C, Tatro L, Hogan W, Massey B. Exaggerated LES rebound contractions following amyl nitrite in achalasia patients: is this inhibitory denervation hypersensitivity? Gastroenterology. 2008 April; 134(4, suppl 1): A-717(W1797).
9. Qumseya B, Naik AS, Ashwin N Ananthakrishnan, Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion DG, Issa M. Increased BMI is not associated with dose escalation or failure of adalimumab therapy in Crohn's disease. Gastroenterology 2009;136(Suppl 1): W1106.
10. Naik AS, Qumseya B, Ashwin N Ananthakrishnan, Zadvornova Y, Skaros S, Beaulieu BD, Johnson K, Perera LP, Binion DG, Issa M. Anti-TNF therapy for Crohn's disease: predictors of dose escalation and early discontinuation by 1 year of therapy. Gastroenterology 2009;136 (Suppl 1): W1102.
11. Beaulieu DB, Ashwin N Ananthakrishnan, Zadvornova Y, Stein DJ, Mepani R, Antonik SJ, Skaros S, Johnson K, Naik AS, Perera LP, Binion DG. Seasonal variation in HRQoL and disease activity in patients with inflammatory bowel disease: a tertiary care center experience. Gastroenterology 2009;136(Suppl 1): M1158.
12. Beaulieu DB, Ashwin N Ananthakrishnan, Zadvornova Y, Stein DJ, Mepani R, Antonik SJ, Skaros S, Johnson K, Naik AS, Perera LP, Binion DG. Does duration of disease impact Health Related Quality of Life (HRQoL) in Inflammatory Bowel Disease? Gastroenterology 2009;136 (Suppl 1): M1156.
13. Venu M, Naik AS, Ashwin N Ananthakrishnan, Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion DG, Issa M. Early Infliximab infusion in hospitalized severe UC patients: one year outcome. Gastroenterology 2009;136(Suppl 1): S1152.
14. Chiplunker A, Ashwin N Ananthakrishnan, Beaulieu DB, Naik AS, Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion DG, Issa M. Long-term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology 2009;136(Suppl 1): S1145.
15. Kumar N, Ananthakrishnan AN, Zadvornova Y, Issa M, Naik AS, Perera LP. Durablility of Infliximab in Ulcerative Colitis: a tertiary center experience. Presented as a poster at Digestive Disease Week 2010.
16. Perera LP, Ananthakrishnan AN, Zadvornova Y, Issa M, Naik AS, Skaros S, Johnson K, Tyler K, Ward A, Massey B. High prevalence of obstructive defecation in Inflammatory Bowel Disease patients in remission. Presented as a poster at Digestive Disease Week 2010.
17. Ananthakrishnan AN, Naik AS, Zadvornova Y, Issa M, Skaros S, Johnson K, Tyler K, Ward A, Perera, LP. Pregnancy and Health Related Quality of Life (HRQoL) in IBD: A tertiary care observational Study. Presented as a poster at Digestive Disease Week 2010.
18. Venu M, Naik AS, Ananthakrishnan AN, Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion D, Issa M. Early Infliximab infusion in hospitalized severe UC patients: two year outcome. Presented as a poster at Digestive Disease Week 2010.
19. Zadvornova Y, Ananthakrishnan AN, Stein D, Skaros S, Johnson K, Naik AS, Perera LP, Issa M. Infliximab monotherapy vs. combined Infliximab-immunomodulator therapy in Ulcerative Colitis. Presented as a poster at Digestive Disease Week 2010.
20. Naik AS, Zadvornova Y, Issa M, Skaros S, Ward A, Johnson K, Tyler K, Stein D, Perera LP, Ananthakrishnan, AN. Tubular Adenoma and Low Grade Dysplasia in Inflammatory Bowel Disease: Who is at risk? Presented as a poster at Digestive Disease Week 2010.
21. Issa M, Zadvornova Y, Naik AS, Stein D, Venu N, Perera LP. High rates of escalation and termination of adalimumab therapy and patients exposed to infliximab. Presented as a poster at Digestive Disease Week 2011.
22. Liu R, Oimoen K, Zadvornova Y, Pruszynski J, Naik AS, Stein D, Venu N, Perera LP. Advanced age at diagnosis does not negatively impact health related quality of life in IBD: Performance of SIBDQ in a longterm cohort study. Presented as a poster at Digestive Disease Week 2011.
23. Issa M, Zadvornova Y, Naik AS, Stein D, Venu N, Perera LP, Binion D, Naik AS. Long-term use of purine analogues in inflammatory bowel disease. Presented as a poster at Digestive Disease Week 2011.
24. Libot A, Issa M, Zadvornova Y, Stein D, Venu N, Perera LP, Naik AS. Initial vancomycin monotherapy is associated with higher rates of subsequent clostridium difficile infection in inflammatory bowel disease population. Presented as a poster at Digestive Disease Week 2011.
25. Chiplunker A, Zadvornova Y, Issa M, Stein D, Perera LP, Venu N, Naik AS. Factors associated with repeat hospitalizations in inflammatory bowel disease. Presented as a poster at Digestive Disease Week 2011.
26. Tarekegn S, Oimoen K, Zadvornova Y, Eastwood D, Issa M, Naik AS, Stein D, Venu N, Perera LP. Biologics are superior to immunomodulators in prevention of post-operative recurrence of Crohn's disease. Presented as a poster at Digestive Disease Week 2011.
27. Perera LP, Zadvornova Y, Binion DG, Guilday C, Stein DJ, Naik AS, Venu N, Best K, Skaros S. 10 year performance of anti TNF biologic therapy in inflammatory bowel disease. Presented as a poster at Digestive Disease Week 2012.
28. Perera LP, Zadvornova Y, Massey BT, Guilday C, Stein DJ, Naik AS, Best K, Skaros S. Increased rate of non-melanoma skin cancer detection with screening skin exam in inflammatory bowel disease: Is it time to recommend routine dermatology care? Presented as a poster at Digestive Disease Week 2012
29. Perera LP, Zadvornova Y, Saeian K, Guilday C, Stein DJ, Naik AS, Venu N, Best K, Skaros S. Durability of Anti TNF α therapy in Ulcerative Colitis: Switching is an Effective Strategy in a Small Subset of patients. Presented as a poster at Digestive Disease Week 2012.
30. Perera LP, Zadvornova Y, Binion DG, Guilday C, Stein DJ, Naik AS, Venu N, Best K, Skaros S. Long term outcomes of crohn’s disease patients on maintenance anti-TNF-α therapy. Presented as a poster at Digestive Disease Week 2012.